What is Zacks Research’s Forecast for Revvity Q3 Earnings?

Revvity Inc. (NYSE:RVTY) – Investment analysts at Zacks Research dropped their Q3 2026 earnings per share estimates for Revvity in a research report issued to clients and investors on Tuesday, May 26th. Zacks Research analyst Team now forecasts that the company will earn $1.33 per share for the quarter, down from their prior forecast of $1.34. The consensus estimate for Revvity’s current full-year earnings is $5.32 per share. Zacks Research also issued estimates for Revvity’s FY2026 earnings at $5.24 EPS and Q2 2027 earnings at $1.42 EPS.

A number of other research firms have also recently commented on RVTY. Robert W. Baird set a $117.00 target price on Revvity in a research note on Wednesday, May 6th. Barclays upped their target price on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Weiss Ratings cut Revvity from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 13th. TD Cowen upped their target price on Revvity from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. cut their target price on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $107.73.

Revvity Trading Up 0.3%

Shares of RVTY stock opened at $104.88 on Monday. Revvity has a 1 year low of $81.22 and a 1 year high of $118.30. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.72 and a quick ratio of 1.41. The stock’s 50 day simple moving average is $92.03 and its two-hundred day simple moving average is $97.27. The company has a market cap of $11.70 billion, a PE ratio of 50.18, a price-to-earnings-growth ratio of 2.25 and a beta of 1.11.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The business had revenue of $711.12 million for the quarter, compared to the consensus estimate of $704.07 million. During the same period in the prior year, the business posted $1.01 earnings per share. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 annualized dividend and a yield of 0.3%. Revvity’s dividend payout ratio is 13.40%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ascentis Independent Advisors bought a new position in Revvity in the first quarter worth approximately $29,000. CYBER HORNET ETFs LLC bought a new position in Revvity in the second quarter worth approximately $32,000. Cromwell Holdings LLC grew its stake in Revvity by 141.4% in the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after purchasing an additional 198 shares in the last quarter. MUFG Securities EMEA plc bought a new stake in Revvity during the 2nd quarter valued at $34,000. Finally, Headlands Technologies LLC bought a new stake in Revvity during the 2nd quarter valued at $49,000. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.